A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Efpeglenatide (Primary) ; Dulaglutide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AMPLITUDE-D
- Sponsors Sanofi
- 29 Oct 2018 Status changed from not yet recruiting to recruiting.
- 24 Sep 2018 Status changed from planning to not yet recruiting.
- 27 Apr 2018 According to a Sanofi media release, the trial is planned to start in Q1 2019.